

Assay Design, Reproducibility Assessment and Downstream Applications for Imaging-Based High-Throughput Phenotypic Profiling (HTPP) Data

Joshua A. Harrill

USEPA Center for Computational Toxicology and Exposure (CCTE)






## Disclaimer

The views expressed in this presentation are those of the author(s) and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency, nor does mention of trade names or products represent endorsement for use.



# Imaging-Based High-Throughput Phenotypic Profiling (HTPP)



Chandrasekaran et al. Nat Rev Drug Discov. 2020 Dec 22:1–15

- A high-throughput testing strategy where rich information present in biological images is reduced to multidimensional numeric profiles and mined for information characteristic to a chemical's biological activity.
- Originated in the pharmaceutical sector and has been used in drug development to understand disease
  mechanisms and predict chemical activity, toxicity and/or mechanism-of-action.




# **Tiered Hazard Evaluation Approach (1)**

- New Approach Methodologies (NAMs) are any technology, methodology, approach or combination thereof that can be used to provide information on chemical hazard and risk that avoids the use of intact animals.
- NAMs are a potential means to reduce the use of animals in toxicity testing and accelerate the pace of chemical risk assessment.
- US EPA CompTox Blueprint advocates the use of high throughput profiling (HTP) assays as the first tier in a NAMs-based hazard evaluation approach.

#### • HTP assay criteria:

- 1. Yield bioactivity profiles that can be used for **potency estimation**, **mechanistic prediction** and evaluation of **chemical similarity**.
- 2. Compatible with multiple human-derived culture models.
- 3. Concentration-response screening mode.
- 4. Cost-effective.



The NexGen Blueprint of CompTox as USEPA Tox. Sci. 2019; 169(2):317-322



# **HTPP with the Cell Painting Assay**

**Cell Painting** is a profiling method that measures a large variety of phenotypic features in fluoroprobe labeled cells *in vitro*.

- High-throughput
- Scalable •
- Amenable to lab automation •
- Deployable across multiple humanderived cell types.
- Reproducible
- Cost-effective (¢ / well) ٠
- Infrastructure investment •
- High volume data management •

#### Laboratory & bioinformatics workflows for conduct of this assay have been established at CCTE.

OPEN	9	ACCESS	Freely	avai	lable	onlin
	-					


#### O PLOS ONE

texture

## Multiplex Cytological Profiling Assay to Measure Diverse Cellular States

Sigrun M. Gustafsdottir<sup>®</sup>, Vebjorn Ljosa<sup>®</sup>, Katherine L. Sokolnicki<sup>na</sup>, J. Anthony Wilson<sup>®</sup>, Deepika Walpita, Melissa M. Kemp, Kathleen Petri Seiler<sup>®C</sup>, Hyman A. Carrel<sup>®d</sup>, Todd R. Golub, Stuart L. Schreiber, Paul A. Clemons<sup>\*1</sup>, Anne E. Carpenter<sup>\*1</sup>, Alykhan F. Shamji<sup>\*1</sup>

Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America








Channels (organelles)

Ы

With illustrations from Perkin Elmer

# **Image Acquisition & Phenotypic Feature Extraction**




## 49 Feature Categories (ex. MITO\_Texture\_Cytoplasm) 1300 features / cell

	Module								
	Position Basic		SCARP morphology				Intensity	Texture	
	[7]	mornh-	Symmetry [80]	Compactness [40]	Axial [20]	Radial [28]	Profile [20-30]	[9]	[14]
DNA			Nuclei	Nuclei	Nuclei	Nuclei Cell	Nuclei Cytoplasm	Nuclei	Nuclei
RNA			Nuclei	Nuclei	Nuclei	Nuclei	Nuclei	Nuclei	Nuclei
ER			Cell	Cell	Cell	Cell	Cytoplasm	Ring Cytoplasm	Ring Cytoplasm
AGP			Cell	Cell	Cell	Cell	Nuclei Cytoplasm	Ring Cytoplasm Membrane	Ring Cytoplasm Membrane
Mito			Cell	Cell	Cell	Cell	Nuclei Cytoplasm	Ring Cytoplasm	Ring Cytoplasm
Not associated with a channel	Nuclei Cell	Nuclei Cell							




# **Examples of Chemical Induced Phenotypes**

Solvent control (0.5% DMSO) Berberine chloride (10 µM)




Mitochondrial Compactness

Solvent control (0.5% DMSO) Ca-074-Me (1 µM)




Golgi Texture

Solvent control (0.5% DMSO) Etoposide (3 µM)




Cell Swelling

Solvent control (0.5% DMSO) Rapamycin (100 µM)



**Cell Compaction** 



• Strong phenotypes are observed qualitatively and produce distinct profiles when measured quantitatively.



# **U-2 OS ToxCast Screen Experimental Design**

Parameter	Multiplier	Notes	
Cell Type(s)	1	U-2 OS	
Culture Condition	1	DMEM + 10% HI-FBS	
Chemicals	1,202	TSCA Chemicals of interest to USEPA Includes 462 APCRA case study chemicals Includes 179 chemicals with annotated molecular targets	
Time Points:	1	24 hours	
Assay Formats:	2	High Throughput Phenotypic Profiling (Cell Painting) High Throughput Transcriptomics (TempO-Seq)	
Concentrations:	8	3.5 log <sub>10</sub> units; ~half-log <sub>10</sub> spacing	
Biological Replicates:	4		



Kavlock et al. (2018) Chem. Res. Tox; 31(5): 287-290 International collaboration of regulatory scientists focused on next generation chemical risk assessment including **deriving quantitative estimates of risk based on NAM-derived potency information and computational exposure estimates.** 


APCRA Chemicals

PK parameters necessary for *in vitro* to *in vivo* extrapolation (IVIVE) *in vivo* toxicity data

Preliminary results. Do not cite or quote.




## **U-2 OS ToxCast Screen Dose Plate Design**



Label	Reference Chemicals:	Molecular Mechanism-of-Action	Test Concentrations	
А	Etoposide DNA topoisomerase inhibitor		0.03 - 10 μM	
В	all-trans-Retinoic Acid Retinoic acid receptor agonist		0.0003 – 1 μM	
С	Dexamethasone	Glucocorticoid receptor agonist	0.001 – 3 μM	
D	Trichostatin A Histone deacetylase inhibitor		1 μΜ	
E	Staurosporine Cytotoxicity control		1 μΜ	
F	DMSO Vehicle control		0.5 %	




# **Assay Performance / Reproducibility**



## ⇒ Reference chemicals produce <u>reproducible</u> and <u>distinct</u> profiles.



# **HTPP Data Analysis Pipeline**




Preliminary results. Do not cite or quote.

#### **EPA** United States Environmental Protection Approaches

Comparison of Approaches for Determining Bioactivity Hits from High-Dimensional Profiling Data

Johanna Nyffeler<sup>1,2</sup>, Derik E. Haggard<sup>1,2</sup>, Clinton Willis<sup>1,3</sup>, R. Woodrow Setzer<sup>1</sup>, Richard Judson<sup>1</sup>, Katie Paul-Friedman<sup>1</sup>, Logan J. Everett<sup>1</sup>, and Joshua A. Harrill<sup>1</sup>

SLAS Discovery 2021, Vol. 26(2) 292–308 © 2020 Society for Laboratory Automation and Screening DOI: 10.1177/2472555220950245 journals.sagepub.com/home/jbx




 Analysis of reference chemicals identified methods that 1) minimized false positives and 2) maximized reproducibility of potency estimates.



# **Phenotype Altering Concentrations (PACs)**

### Mahalanobis Distance (D<sub>M</sub>):


- A multivariate metric that measures the distance between a treatment and a distribution of controls in feature space.
- Accounts for unpredictable changes in cell states across test concentrations and inherent correlations in profiling data.



- Chemicals where a BMC can be determined using either the global or category D<sub>M</sub> approach are considered active.
- The minimum of the global or most sensitive category BMC is the **Phenotype Altering Concentration (PAC)**




# **Reproducibility: Potencies**



⇒ Potency estimates vary less than ½ an order of magnitude




## **U-2 OS ToxCast Screen Results**



⇒ Potency estimates vary less than ½ an order of magnitude



# *In Vitro* to *In Vivo* Extrapolation (IVIVE) & Comparison to *In Vivo* Toxicity Data & Exposure Estimates




POD: point-of-departure AED: administered equivalent dose



# **Comparison to In Vivo Effect Values & Other NAMs**


• 303 chemicals were active and had pharmacokinetic (PK) information




- → HTPP AEDs are higher than ToxCast-derived AEDs and TTC values
- ⇒ 78% of HTPP AED are within 2 orders of magnitude of the *in vivo* POD



# **Comparison to Exposure Estimates**



- ⇒ for 49% of chemicals, predicted exposure is > 1000x lower than estimated bioactivity
- ➡ for a small set of chemicals, the BER was negative, indicating a potential for humans to be exposed to bioactive concentrations of these chemicals





# **Summary and Conclusions**

- **High-Throughput Profiling:** Developed experimental designs and scalable laboratory workflows for high-throughput phenotypic profiling (HTPP) of environmental chemicals that can be used in multiple human-derived cell types.
- **Potency Estimation:** Developed high-throughput concentration-response modeling workflows to identify thresholds for perturbation of cell morphology (e.g. PACs).
- IVIVE: Potency estimates can be converted to administered equivalent doses (AEDs) using high-throughput toxicokinetic modeling.
- **Bioactivity to** *In Vivo* Effect Value Ratio Analysis: AEDs derived from the HTPP assay were conservative or equivalent to traditional PODs a majority of the time.
- **Bioactivity to Exposure Ratio (BER) Analysis:** AEDs derived from the HTPP assay were compared to high-throughput exposure predictions. There were very few chemicals where AEDs were within the range of exposure predictions.
- **Comparison to ToxCast:** Applications using HTPP NAMs potencies as input yielded comparable results compared to the use of ToxCast NAMs potencies.



# Acknowledgements



Office of Research and Development (ORD) Center for Computational Toxicology and Exposure (CCTE)

- Johanna Nyffeler
- Clinton Willis
- Rick Brockway
- Megan Culbreth
- Dan Hallinger
- Terri Fairley
- Ann Richard
- Kathy Coutros
- Maureen Gwinn
- Russell Thomas

- Katie Paul-Friedman
- Logan Everett
- John Wambaugh
- Woody Setzer
- Imran Shah
- Richard Judson
- Derik Haggard



- Joe Trask
- Dana Hanes
- Jim Hostetter